Citation Impact
Citing Papers
A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation
2002 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
1997
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
2008 Standout
Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design
2004
Heart-Rate Profile during Exercise as a Predictor of Sudden Death
2005 Standout
Long-Term Trends in the Incidence of and Survival with Heart Failure
2002 Standout
Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program
2008
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure
2008
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation
2007
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Clinical trials of arrhythmia management: Methods or madness
1996
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
2003 Standout
Pulmonary Effect of Amiodarone in Patients With Heart Failure
1997
The Failing Heart — An Engine Out of Fuel
2007 Standout
The Quality of Health Care Delivered to Adults in the United States
2003 Standout
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
2000
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
2005
Efficacy of Ranolazine in Patients With Chronic Angina
2009
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts — Role of late sodium current and intracellular ion accumulation
2008
Anti-anginal effects of partial fatty acid oxidation inhibitors
2007
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation
2002
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Clinical Benefits of a Metabolic Approach with Trimetazidine in Revascularized Patients with Angina
2006
Thyroid Hormone and the Cardiovascular System
2001 Standout
Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome
2009
Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris
2005
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
2003 Standout
Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia
1995
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?
1998
A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease
1999 Standout
Antiarrhythmic Therapies for the Prevention of Sudden Cardiac Death
1997
Ranolazine for chronic stable angina
2008
Prevention of Heart Failure
2008
Trends in Heart Failure Incidence and Survival in a Community-Based Population
2004 Standout
Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts
2006
Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis
2005
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
2003 Standout
Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia
1996 Standout
Randomised trial of low-dose amiodarone in severe congestive heart failure
1994
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
1996
Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy
2013 Standout
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
2001 Standout
How were new medicines discovered?
2011 Standout
A Comparison of Seven Antiarrhythmic Drugs in Patients with Ventricular Tachyarrhythmias
1993
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
1997
A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation
2002 Standout
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure<SUBTITLE>The EVEREST Outcome Trial</SUBTITLE>
2007 Standout
Ranolazine, a Novel Agent for Chronic Stable Angina
2006
Improving survival for patients with advanced heart failure: A study of 737 consecutive patients
1995
Heart failure
2005
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
1997 Standout
Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine
2006
Adjunctive Drug Therapy of Acute Myocardial Infarction — Evidence from Clinical Trials
1996
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
2003
The Management of Hypertrophic Cardiomyopathy
1997
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
A Comparison between Ranolazine and CVT-4325, a Novel Inhibitor of Fatty Acid Oxidation, on Cardiac Metabolism and Left Ventricular Function in Rat Isolated Perfused Heart during Ischemia and Reperfusion
2007
Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications
1995
Improved Left Ventricular Function and Reduced Necrosis after Myocardial Ischemia/Reperfusion in Rabbits Treated with Ranolazine, an Inhibitor of the Late Sodium Channel
2006
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
2003 StandoutNobel
Transition‐Metal‐Catalyzed Direct Arylation of (Hetero)Arenes by CH Bond Cleavage
2009 Standout
Sympathetic activation, ventricular repolarization and Ikrblockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents
1995
Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine
2006
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
2015 Standout
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction
2007
Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes<SUBTITLE>The MERLIN-TIMI 36 Randomized Trial</SUBTITLE>
2007
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
2005 Standout
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
2003
Valsartan
2004
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
2009 Standout
New Roles for β-Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors
2006 StandoutNobel
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
A Decade of Clinical Trial Developments in Postmyocardial Infarction, Congestive Heart Failure, and Sustained Ventricular Tachyarrhythmia Patients: From CAST to AVID and Beyond
1998
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias
1997 Standout
Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials
2004
Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions
2006
Myocardial Fatty Acid Metabolism in Health and Disease
2010 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome
2007
Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure
2009 Standout
Ranolazine in patients with coronary artery disease
2007
Sudden Cardiac Death
1998 Standout
Metabolic Modulators for Chronic Cardiac Ischemia
2005
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device
2009 Standout
Review: Prospects for ARB in the next five years
2001
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial
2004
Biologic actions and pharmacokinetic studies of auranofin
1983
Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study)
1993
Heart-specific autoantibodies induced by Coxsackievirus B3: Identification of heart autoantigens
1987
Clinical End Points in Coronary Stent Trials
2007 Standout
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
2008
Ranolazine, an Inhibitor of the Late Sodium Channel Current, Reduces Postischemic Myocardial Dysfunction in the Rabbit
2006
Canadian Implantable Defibrillator Study (CIDS): Study design and organization
1993
Antiarthritic Gold Compounds Effectively Quench Electronically Excited Singlet Oxygen
1987 StandoutScienceNobel
The Effects of Amiodarone on the Thyroid*
2001
The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population
2007
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2011
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of J Kuch being referenced
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
1999
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
2000
Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study
1992
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina
2004
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
2004
Adjuvant-Induced Arthritis in Rats I. Temporal Relationship of Physiological, Biochemical, and Hematological Parameters
1971
Ranolazine increases exercise performance and decreases hemoglobin A1C in angina patients with diabetes
2003
Autoantibodies directed against heart antigens and endocrine reactivity in patients with recent myocardial infarction
1973